Equities Analysts Provide Earnings Predictions for Arcus Biosciences in FY2025

Arcus Biosciences, Inc. (NYSE:RCUS) has recently drawn the attention of analysts, particularly Cantor Fitzgerald, which released its estimates for the company’s fiscal year 2025 earnings. According to a research report issued on January 21st, analyst L. Watsek anticipates that Arcus Biosciences will report earnings per share of ($5.29) for the fiscal year. Additionally, Cantor Fitzgerald has assigned an “Overweight” rating to the stock, suggesting a positive outlook for its performance.

The current consensus among analysts for Arcus Biosciences’ earnings stands at ($3.20) per share for the year. This indicates a more optimistic perspective compared to Cantor Fitzgerald's estimate.

Arcus Biosciences released its most recent earnings results on November 6th, where it reported an earnings per share (EPS) figure of ($1.00). This result exceeded the analysts' consensus estimate of ($1.06) by $0.06, indicating that the company may be performing better than expected. Despite this, the company recorded a negative net margin of 102.66% and a return on equity of -45.59%. Revenue during the quarter amounted to $48.00 million, which significantly outperformed analyst expectations of $38.95 million. Notably, this was a substantial 50.0% increase from the prior year’s revenue.

In addition to Cantor Fitzgerald, several other brokerage firms have recently shared their perspectives on the stock. HC Wainwright reiterated a “neutral” rating with a price target of $20.00 on Arcus shares. Meanwhile, Wells Fargo & Company initiated coverage on the stock, giving it an “overweight” rating and setting a target price of $29.00. Wedbush also provided an upbeat assessment, restating an “outperform” rating with a price objective of $36.00. Furthermore, Barclays raised their price target for the stock from $25.00 to $29.00 and maintained an “overweight” rating. Overall, the market shows a favorable inclination toward Arcus Biosciences, with one hold rating, seven buy ratings, and one strong buy rating from analysts. MarketBeat.com reports a consensus rating of “Buy” along with an average price target set at $34.00.

Arcus Biosciences Stock Performance Overview

As of Wednesday, shares of Arcus Biosciences (NYSE: RCUS) opened at $13.41. The stock has navigated within a 12-month low of $13.40 and a high of $20.31, while holding a market capitalization of approximately $1.23 billion. The company has a price-to-earnings (PE) ratio of -4.26 and a beta of 0.87, reflecting its stock volatility relative to the market. Further technical analysis indicates a 50-day simple moving average of $15.40 and a 200-day simple moving average of $15.92. Arcus boasts a strong liquidity position, demonstrated by a current ratio of 5.24 and a quick ratio of the same value, coupled with a conservative debt-to-equity ratio of 0.08.

Recent Insider Activities

In recent insider trading news, Chief Financial Officer Robert C. Goeltz II sold 3,594 shares on December 31st at an average price of $15.00, totaling $53,910. After this sale, the CFO holds 60,138 shares in the company, valued at approximately $902,070, reflecting a decrease of 5.64% in their holdings. The transaction was disclosed in a filing with the Securities and Exchange Commission. Overall, company insiders currently own 12.30% of the stock, indicating a significant management stake.

Institutional Investment Activity

Large institutional investors have also been active concerning Arcus Biosciences shares. American Century Companies Inc. increased its stake by 22.5% in the second quarter, now owning 70,917 shares valued at $1,080,000 after acquiring an extra 13,019 shares. Additionally, XTX Topco Ltd. made a new investment in the company worth around $590,000 during the same quarter. The Public Sector Pension Investment Board enhanced its position by 7.4%, holding 120,099 shares valued at $1,829,000 after an additional 8,253 shares purchase. Point72 DIFC Ltd and Cubist Systematic Strategies LLC are also among the institutional investors that have made new acquisitions in Arcus, highlighting the interest from large investors. Notably, institutional investors and hedge funds collectively account for 92.89% of the stock ownership.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer therapies within the United States. Its pipeline includes Domvanalimab, an anti-TIGIT antibody presently undergoing Phase 2 and Phase 3 clinical trials, as well as AB308, an investigational anti-TIGIT monoclonal antibody being evaluated in a Phase 1b clinical trial for patients with advanced solid and hematologic malignancies.

Arcus, Biosciences, Earnings